ST Germain D J Co. Inc. Acquires 64,208 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on Jun 17th, 2023

ST Germain D J Co. Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 38.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 232,572 shares of the company’s stock after buying an additional 64,208 shares during the quarter. Johnson & Johnson comprises 3.8% of ST Germain D J Co. Inc.’s portfolio, making the stock its 6th biggest holding. ST Germain D J Co. Inc.’s holdings in Johnson & Johnson were worth $11,226,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of JNJ. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $35,000. GW&K Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $35,000. Dark Forest Capital Management LP grew its position in shares of Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the last quarter. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $40,000. Finally, Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $42,000. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $164.23 on Friday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The firm has a 50 day moving average of $160.73 and a 200-day moving average of $164.06. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $426.79 billion, a P/E ratio of 34.36, a price-to-earnings-growth ratio of 2.76 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the previous year, the company posted $2.67 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were issued a $1.19 dividend. The ex-dividend date of this dividend was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. Atlantic Securities lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price for the company. Citigroup initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price for the company. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $171.57.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.